Introduction
Radiation therapy, either administered through external beam or seed implantation (brachytherapy), remains a popular therapeutic modality for treatment of clinically localized prostate cancer (CAP). Due to a large number of patients treated by this modality, an increasing number of patients are presenting local failure. It has been demonstrated that clinical recurrence both predicts and causes ultimate disease dissemination. 1±3 The impact of radiation failure in patients with prostate cancer can be measured in terms of its effect on patient survival. Patients with local recurrence after de®nitive radiation therapy have shorter disease speci®c survival as well as a four-fold increased risk for metastasis compared to patients with apparent local control. Morbidity due to tumor progression is likewise signi®cant and includes pain, gross hematuria, bladder outlet and ureteral obstruction, uremia and the many effects of distant metastasis. A signi®cant number of patients eventually require a transurethral resection of the prostate (TURP) or other forms of urinary diversion to relieve obstruction. Of major concern is the almost 30% incidence of incontinence in these who undergo TURP following radiation. 4 
De®nition
Recurrence following radiotherapy for localized prostate cancer can be de®ned in many ways. Clinically, it may present with signs and symptoms of obstruction, either of the bladder outlet or the ureters. It often presents with a new-found prostatic nodule or progression of local disease based on digital rectal examination (DRE). Of course, de®nitive diagnosis requires histologic examination of tissues, generally obtained from prostate needle biopsy or less commonly, from TURP specimen. In recent years, the most common indication for evaluation of an individual for the potential of radiation failure is a rising prostatic speci®c antigen (PSA) or failure to achieve a PSA nadir.
The true incidence of clinical local recurrence after radiation is not clear. The diagnosis of recurrence by DRE, although readily available and inexpensive, is dif®-cult, except for cases of gross tumor recurrences. Small focus of residual tumor are often indistinguishable from background ®brosis brought about by irradiation. This dif®culty in the interpretation of DRE in the setting of post-irradiation has been well documented in the litera-ture. It has been shown that as low as 20% to as high as 80% of patients with positive post-irradiation biopsies may indeed have a normal digital rectal examination.
5±7
In an attempt to detect early cases of radiation failure, a number of investigators have performed postradiation prostatic biopsies based on the premise that microscopic recurrence precedes and is more frequent than clinical recurrence, and this could lead to earlier institution of salvage therapies. 8±10 However, the concept of microscopic recurrence have been questioned. It was previously proposed that a positive biopsy within 18 months of radiotherapy had no biologic signi®cance and does not correlate with disease progression. 11 This study group however, included patients who had received hormonal therapy, which potentially, could promote local tumor regression, alter the course of the disease and cause false negative biopsies. In vitro studies conducted by Musselman et al 12 using tissue culture demonstrated the viability of the post-irradiated prostate cancer cells. Long term follow-up of patients who did not receive hormones revealed that patients failing radiation therapy have worse prognosis and survival than those with negative biopsies (Tables 1 and 2) . 5,7,9,10,13±30 Nevertheless, post-radiation prostate biopsy does not always predict eventual clinical recurrence. About 20% of patients with positive postradiation prostate biopsies have no evidence of disease at 10 y follow-up. 7, 31 Undoubtedly, some positive biopsies may detect clinically latent cancers. Equally important is the almost 30% incidence of local and distant recurrences occurring in those with negative postradiation biopsies. Although some of these cases may actually have micrometastasis at presentation, sampling errors could occur during the biopsy procedure, which could lead to less than ideal pick-up rates. Of utmost importance is the realization of the fact that confusion in the interpretation of the pathological picture can be brought about by radiation atypia in the benign prostate gland, which potentially could lead to a false positive biopsy result. 32 Immunohistochemical technique using basal cellspeci®c cytokeratin monoclonal antibodies have been shown to be useful in differentiating benign glands from malignant ones, with only the benign glands displaying immunoreactivity, and thus, is a useful adjunct to surgical pathologic diagnosis in a post-radiation setting. 33, 34 Transrectal ultrasonography (TRUS) has been investigated in the postradiated prostate. Although it has been shown by some that persistent foci of malignancy retained their hypoechoic appearance after radiation and successfully treated areas reverted to isoechogenecity, 35, 36 this has not been the universal experience as shown by Kabalin et al, 5 showing 65% of biopsied sectors were positive. Nevertheless, TRUS is valuable as a guidance tool to enhance detection of recurrence, as clearly illustrated by Egawa et al 37 showing 67% detection rate compared to the 22% for the digital biopsies.
During the past decade, serum PSA has emerged as the most useful tumor marker, both in the diagnosis as well as in monitoring disease status following treatment. A rising PSA following de®nitive treatment is a harbinger for residual or recurrent disease in almost all cases. 38, 39 Unlike radical prostatectomy, radiation therapy does not immediately eradicate all PSA-producing cells, and therefore, the persistence of a detectable PSA does not necessarily mean the presence of cancer. PSA levels decline gradually following radiation, reaching nadir levels 1±2 y after treatment. Although the`normal' PSA level after radiation has not been clearly de®ned, it is universally accepted that a persistently rising PSA following radiation is a hallmark of biochemical relapse and signal impending recurrence (Table 3) . 27 ,29,30,40±55
Patient evaluation
Patients suspected of having recurrent CAP, either due to suspicious DRE or by rising PSA or failure to achieve a PSA nadir, should undergo a prostate needle biopsy, preferably with TRUS guidance to establish the diagnosis of local recurrence. Metastatic workup in the form of bone radioscintigram and occasionally, computerized tomographic (CT) scan or magnetic resonance imaging (MRI) of the abdomen and pelvis as well as chest radiograph should be performed. Unlike in the non-irradiated patients wherein a PSA of`10 ng/ml is rarely associated with bone metastasis, 56 the same cannot be said in this situation. Potential candidates for salvage procedures should undergo a complete medical evaluation to rule out associated clinical conditions that could adversely affect the life span of the patient. Likewise, cystoscopy should be performed to evaluate possible bladder involvement and assess the functional status of the bladder. A small contracted bladder even in the face of minimal residual disease or bladder involvement indicates the necessity for a more extensive surgery.
Salvage surgery after radiotherapy
The goal of salvage surgery after radiation failure is to remove all remaining viable cancer cells within the prostate in order to produce local control and de®nitive cure. This is a technically challenging procedure, and therefore, candidates considered for this procedure must be highly motivated individuals willing to accept the potential higher morbidity of the surgical undertaking of this magnitude. They should be in very good health, with no signi®cant co-morbid disease and at least ten years of life expectancy. They should have had clinically organ con®ned cancer at the time of radiation, and remain so at the time of contemplated salvage surgery. Generally, these patients are those that would have been suitable candidates for radical prostatectomy at the time of initial diagnosis.
Moreover, owing to the technical demands associated with extirpation following de®nitive radiation therapy, such attempts should be undertaken only by individuals with vast experience in performing radical prostatectomy and other pelvic exenterative procedures. Surgeons should be well-versed in dealing with troublesome bleeding, rectal injury and dif®culty in creation of appropriate surgical planes in an operative ®eld frequently devoid of the natural demarcation between the prostate gland and adjacent organs.
Salvage surgery can be performed in several ways. Radical prostatectomy is the procedure of choice and is indicated when it is believed that the neoplasm is organ con®ned. It is important that there be no suspicion of extension to the pelvic side walls or involvement of the bladder base or trigone. Anterior exenteration or total pelvic exenteration has been proposed for patients with extensive extra-prostatic, bladder or rectal involvement.
Salvage operations, especially radical prostectomy for radiation failure are potentially curative as reported by several investigators (Table 4) . 57±64 Five-year cause speci®c survival of 60±95% and 10 y cause speci®c survival of 40±87% have been reported. One of the biggest series was reported by Lerner et al 63 from the Mayo Clinic Foundation reporting the result of 132 patients who underwent salvage surgery from 1967±1992. The 10 y cancer-speci®c survival rate for the 79 patients who underwent salvage prostatectomy was 72%, which was signi®cantly better than the anterior and total exenteration group, although the local control was equivalent among the three surgical groups. It should be emphasized however, that almost 40% of those who underwent prostatectomy had organ con®ned disease compared to only 16% of those who underwent anterior exenteration and none for total pelvic extenteration. This underscores the importance of proper patient selection as the best result can only be expected from the group of patients with clinical stage T2 or less cancer and with PSA detected radiation failures. After irradiation, the signi®cant ®brosis with resultant obliteration of the surgical planes make dissection more dif®cult, resulting in higher incidence of rectal injuries. An ingenious and simple procedure using¯aps of endopelvic fascia to reinforce rectal repair and isolate the injury from the pelvic space and urethral anastomosis has been reported previously. 65 Fibrosis involving the bladder neck and sphincteric tissues and compromised vasculature may result in poor wound healing with higher incidence of prolonged urinary extravasation and vesico-urethral anastomotic leakage, increased incidence of bladder neck contracture and incontinence. Erectile dysfunction should be expected to occur in virtually all cases since little or no effort is made to preserve the neurovascular bundles. Table 5 summarizes the more common complications encountered in several series of salvage surgery in this setting. 57±64,66 With the more liberal utilization of post-treatment PSA as a surveillance tool for response to therapy and the availability of TRUS-guided prostate needle biopsy, earlier detection of a subgroup of ideal patients can be identi®ed and potentially be cured with salvage radical prostatectomy. It is encouraging to note the decreased complication rate and transfusion requirement seen in later series of salvage prostatectomy. 63 With further experience and improvement in surgical technique and instrumentation, results approaching that of the standard radical retropubic prostatectomy may ultimately be achieved.
Cryoablation
Modern prostate cryotherapy is actually a resurgence of an old concept. Although early series using open perineal cryoablation of the prostate in humans revealed comparable survival rates with radical prostatectomy, 67 it was fraught with unacceptable complications of urethrorectal and urethrocutaneous ®stula, bladder neck obstruction, stress incontinence and prolonged tissue sloughing with resultant urinary obstruction. Cryotherapy, was therefore, abandoned not because of ineffective tumor destruction but due to its unacceptably high complication rate.
The development of high resolution transrectal ultrasonography with the ability for multiplanar imaging of the prostate and surrounding structures allows safe and accurate cryoprobe placement into the prostate. Due to the ultrasonically impenetrable nature of ice crystals that form in the prostate gland, sound waves are unable to pass through and thus appears as an advancing hyperechoic line with anechoic shadow. Improvement In the technical aspect and better instrumentation with the use of needles, guidewires, fascial dilators and sheaths allows up to ®ve separate cryoprobe delivery simultaneously to different parts of the prostate. Furthermore, modern cryotherapy delivery system possess the ability to circulate liquid nitrogen at 7180 C to 7200 C at different rates of freezing, allowing precise, controlled and thorough tissue destruction.
68±71
In a broad perspective, cryosurgery causes cell injury by creating a hyperosmolar state within the cell, protein denaturation, membrane disruption and microvascular destruction. Hypothermia leads to decreased intracellular energy stores and breakdown in the physical and physiological functions of the cellular membrane. Ice crystals form in the extracellular space as well as cell membrane gap junction, eventually leading to formation of intracellular ice, exerting mechanical shearing effects on the cytoskeletal structures, organelles and cell membranes. The thawing process will lead to a markedly hypotonic environment with a relative hyperosmolar state intracellularly, causing osmotic in¯ux of free water leading to cellular swelling and eventual cell lysis and cell death. Likewise, concomitant microvessel injury and thrombosis occurs resulting to a superimposed ischemic insult 72, 73 and furthermore, near freezing temperatures at the periphery of the frozen region may act as a signal for apoptosis or programmed cell death. 74 A double freeze-thaw cycle involves two distinct freezing episodes separated by a complete thawing period. This is believed to achieve a potentially more unfavorable condition for the cells in the treated ®eld and for extending areas of whose temperature is marginal, affording a more thorough and effective freezing process.
75±77
The relative non-invasiveness of cryosurgery is its major advantage. Since an incision is avoided, minimal blood loss and post-procedure pain can be expected, making this procedure better tolerated than open surgery. This is potentially advantageous in individuals who would not be candidate for salvage prostatectomy due to advanced age or comorbid conditions. Another advantage is the potential to manage extracapsular extension which could not be treated by salvage prostatectomy. Furthermore, the freezing process is effective against a biologically diverse cancer cell population, including androgen independent and chemoresistant cells. Caution however, must be exercised because of is potential to injure adjacent structures including the ureter, bladder and rectum.
A number of publications have described the ef®cacy of primary cryotherapy as a treatment option for prostate cancer using post-treatment PSA and prostate biopsy endpoints (Table 6) . 69,78±85 The biggest experience regarding prostatic cryoablation in the setting of radiation failures is by the MD Anderson Cancer Center group. Since July of 1992, over 150 salvage cryoablation procedures have been performed, 110 of which were directed towards radiation failure. 85 Half of the patients in this series had high grade cancer, compared to less than 10% of those patients at the time of initial diagnosis. Forty-nine patients underwent a single freeze-thaw cycle and 51 underwent two freeze-thaw cycles. Almost all (96%) of the patients demonstrated a decline in PSA levels after the procedure, 77% had a fall in PSA to`4.0 ng/ml and 37% had an undetectable PSA. Fifty-eight patients unfortunately had a subsequent rise in PSA following its nadir, although only 4 of the 37 patients with undetectable PSA nadir developed a subsequent PSA rise after a mean follow-up of 11.7 months.
Postcryotherapy prostate needle biopsy was performed in 82 patients either on a routine basis at six months follow-up or earlier to evaluate clinical evidence of progression as manifested by a rise in PSA or bladder outlet obstruction. Sixty-seven of the 82 patients had a negative biopsy. Of the 15 (19%) patients having persistent cancer, eight had only a focally positive biopsy, suggesting the possibility of complete tumor eradication with another session of cryotherapy. It is interesting to note that only three out of 38 patients who received double freeze treatment showed positive biopsy compared to 12 out of the 44 patients who received a single freeze treatment regimen.
This procedure is not devoid of complications however, with incontinence and impotence being the most prominent. Only 27% of patients in the MD Anderson study reported total urinary control with the rest being incontinent ranging from slight to total urinary leakage. It is worth emphasizing however, that the incontinence rate is no different from that following salvage radical prostatectomy. Likewise, of the 46 patients that were potent prior to treatment, 72% are rendered impotent by the procedure. Other complications includes pain, urinary obstruction, some of them requiring TURP, a case of prostatic abscess and a case of urethrorectal ®stula which closed spontaneously.
Androgen ablation
The use of androgen ablation in the adjuvant setting for patients with radiation failure for prostate cancer has not been evaluated in a prospective manner. The biggest 31 Moreover, more than half of these patients require a transurethral resection of the prostate and a number of others require additional urinary diversion procedures for symptoms of obstruction brought about by local tumor progression. Being the most conservative, least morbid and the most easily administered therapy for prostate cancer, perhaps, this modality is the most appropriate for the majority of men who probably are not ideal candidates for salvage surgical procedures.
Repeat irradiation
Very little information is currently available regarding the ef®cacy of performing repeat irradiation in the setting of radiation failure. Existing data suggests borderline control of the tumor at the expense of very high morbidity, particularly severe urinary incontinence or rectal complications. 87, 88 The use of ultrasound-guided transperineal seed implantation by Blasko 89 eliminated the incidence of rectal complications, although the urinary incontinence rate of 30% was noted.
Recent advances employing three dimensional conformal radiotherapy have been shown to reduce the radiation dose to the bladder and rectum, thus, potentially further reducing morbidity.
Gene therapy
A lot of interest has been generated in the search for molecular markers to de®ne the genetic basis of prostate cancer as well as offering the prospect of gene therapy. In prostate cancer, the modality can be classi®ed into local and systemic gene therapy. 90 Local gene therapy involves restoration of tumor suppressor genes, destruction of local growth factors and utilization of direct cellular toxins. Obviously, metastatic disease requires systemic gene therapy, which usually involves a vaccination approach with gene modi®ed tumor cells. This modality is currently in its infancy and its true ef®cacy will not be known until after results of large randomized phase III controlled trials have been done.
Conclusions
Patients suspected of having recurrence following radiation therapy either clinically or biochemically requires histologic con®rmation by performance of a prostate needle biopsy. Restaging imaging studies as well as complete medical evaluation for co-existing clinical conditions must be performed. There is de®nitely a subset of patients with locally recurrent prostate cancer without evidence of metastasis that could potentially bene®t from aggressive local therapy.
Salvage surgery may offer long term cancer control in properly selected patients. Although earlier experience indicates high morbidity, it is encouraging to note the decreased complication rate and transfusion requirement in newer series. The patient is obviously best served if this procedure is performed only by individuals with extensive experience.
Of course, the age-old controversy with respect to the ef®cacy of therapy for those that truly need it and the ability to achieve a therapeutic response in those destined to do well without it remains. In the absence of randomized trials, these issues cannot be resolved. This then leads to the central dilemma in counselling of patients as to their treatment options in the face of radiation failure. We continue to recommend therapy with curative intent in properly selected patients, making clear, of course, that the associated morbidity may be considerable and the ultimate bene®t that the individual will accrue unknown.
Cryoablation is less invasive and is more attractive to patients with comorbidities, but its long-term ef®cacy remains to be determined. A treatment algorithm is proposed as shown in Figure 1 for management of patients with primary radiation failure. It should be emphasized however that this is just a guide and treatment options should be individualized to suit the need of the particular patient.
In the future, novel energy sources such as radiofrequency and microwave will undoubtedly be tried in men with radiation failure. Clearly, more research is necessary in order to de®ne the optimal therapeutic approach for this dif®cult patient population.
